Streetbeat News

Stock Prices

TELA

TELA Bio (NASDAQ:TELA) reported Q4 earnings with an EPS of $-0.53, missing estimates by -23.0% against an expected $-0.43. Revenue increased by $5.38 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 19.0% the following day. The company's past earnings performance shows a mixed trend of beating and missing EPS estimates.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:20 pm

ASXC

Asensus Surgical (AMEX:ASXC) reported Q4 earnings, beating estimates with an EPS of $-0.07 against an expected $-0.08. Revenue increased by $2.97 million year-over-year. Despite beating last quarter's EPS estimate, the share price dropped by 6.0% the following day.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:20 pm

TIP

Former U.S. Treasury Secretary Lawrence Summers criticized the Federal Reserve's plans to cut interest rates amidst a strong economy and high inflation. He questioned the Fed's eagerness, citing the economy's performance and the need for a higher neutral interest rate than the Fed's forecast. Financial conditions have loosened, as indicated by the Chicago Fed National Financial Conditions Index, while inflation expectations remain above the Fed's target, as shown by the 5-year breakeven rate.

Portfolio Pulse from Piero Cingari

March 21, 2024 | 8:18 pm

BIOL

Biolase (NASDAQ:BIOL) reported Q4 earnings with losses of $(1.76) per share, surpassing the $(2.55) estimate, marking a significant improvement from last year's $(128.00) per share. However, their $13.49M in sales fell slightly short of the $13.55M estimate, representing a 3.99% decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 8:16 pm

CRBG

Recent options trading activity for Corebridge Financial (NYSE:CRBG) shows a bearish sentiment among significant investors, with 55% of detected trades being bearish. The trading activity suggests a target price range of $25.0 to $28.84. Corebridge Financial's stock is currently up by 1.1%, trading at $27.53. The company is a provider of retirement solutions and insurance products, with the majority of its revenue coming from the Individual Retirement segment.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:16 pm

ANF

Abercrombie & Fitch (NYSE:ANF) has seen unusual options activity indicating a bullish sentiment among deep-pocketed investors, with a significant portion aiming for a price range of $110.0 to $185.0. The activity includes both calls and puts, with a higher volume in calls. Current trading volume is 1,336,792, with a 1.21% price increase to $136.68. Analysts have mixed ratings, with an average price target of $132.4. The company is a specialty retailer with a global presence.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:16 pm

HQI

HireQuest (NASDAQ:HQI) reported Q4 earnings with an EPS of $0.03, beating estimates by 150% against an expected -$0.06. Revenue increased by $1.72 million year-over-year. This contrasts with the previous quarter where the company missed EPS estimates by $0.07, leading to an 18% share price drop the following day.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:15 pm

AMPX

Amprius Technologies (NYSE:AMPX) reported its Q4 earnings on March 21, 2024, with an EPS of $-0.11, matching estimates. Revenue increased by $3.15 million year-over-year. Despite meeting EPS estimates this quarter, the company had previously beaten EPS estimates in Q3 2023, which led to an 18.0% share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:15 pm

HQI

HireQuest (NASDAQ:HQI) reported Q4 earnings of $0.03 per share, surpassing the $(0.06) estimate, marking a 150% beat. Year-over-year, earnings decreased by 84.21% from $0.19 per share. Q4 sales reached $9.76M, exceeding the $8.60M estimate by 13.53% and showing a 21.31% increase from last year's $8.05M.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 8:13 pm

FDX

FedEx has updated its FY24 EPS guidance to $17.25-$18.25, with permanent cost reductions from the DRIVE transformation program amounting to $1.8 billion. The company expects a low-single-digit percentage decline in revenue year over year but has improved its earnings forecast before MTM retirement plans accounting adjustments. Capital spending is now projected at $5.4 billion, down from $5.7 billion, focusing on efficiency improvements. These forecasts are based on current economic and fuel price expectations, planned stock repurchases, and no new adverse geopolitical developments.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 8:12 pm